Sage Therapeutics Acquisition | Maryland Drugmaker Deal
supernus Pharmaceuticals, a maryland-based drugmaker, will acquire Sage Therapeutics in a deal potentially reaching $795 million, a move poised to reshape the brain health treatment landscape. This strategic acquisition, expected to close in the third quarter, signals Supernus’s commitment to expanding its portfolio. Sage Therapeutics,based in Cambridge,Massachusetts,will become a part of Supernus. The decision followed a strategic review by Sage’s board, according to the proclamation.
The acquisition is a pivotal moment for both companies, promising growth and new opportunities. CEO Barry Greene of Sage expressed his gratitude to colleagues and said the move should maximize shareholder value. News Directory 3 will provide updates regarding this deal’s importance.Discover what’s next for these companies.
Supernus Pharmaceuticals to Acquire Sage Therapeutics in $795M Deal
Updated June 16, 2025
Supernus Pharmaceuticals, based in Maryland, has reached an agreement to acquire Cambridge, Mass.-based Sage Therapeutics. the deal, focused on expanding Supernus’s role in brain health treatments, could be worth up to $795 million.
The companies anticipate finalizing the acquisition in the third quarter. The move follows a strategic review by Sage’s board.
Sage CEO Barry Greene expressed gratitude to his team. He believes the acquisition maximizes value for shareholders. Greene said the company looks forward to its next chapter with Supernus.